OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-Mediated ERK1/2/NF-κB Pathway in RAW264.7 Cells

Journal of Interferon and Cytokine Research

Volumn 34, Issue 7, 2014, Pages 526-536

  Luan, Hong ^a   Zhang, Qian ^a   Wang, Le ^a   Wang, Chuanxiao ^b,c   Zhang, Miao ^d   Xu, Xiaoli ^a   Zhou, Huan ^a   Li, Xing'Ai ^a   Xu, Qing ^a   He, Fan ^a   Yuan, Jin ^a   Lv, Yongman ^a  

^a Tongji Hospital   (China)

^b Xiehe Hospital   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Angiocardiopathy Internal Department   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; BACTERIUM LYSATE; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELOID DIFFERENTIATION FACTOR 88; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TUMOR NECROSIS FACTOR ALPHA; BRONCHO-VAXOM; CELL EXTRACT; IMMUNOLOGICAL ADJUVANT; TLR2 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; IMMUNE RESPONSE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BLOTTING, WESTERN; CELL EXTRACTS; CELL LINE; CYTOKINES; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84903795150     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0077     Document Type: Article

References (37)

1. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124(4):783-801. (Pubitemid 43261452)
2. Alyanakian MA, Grela F, Aumeunier A, Chiavaroli C, Gouarin C, Bardel E, Normier G, Chatenoud L, Thieblemont N, Bach JF. 2006. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 55(1):179-185. (Pubitemid 43343313)
3. Baeuerle PA, Baltimore D. 1996. NF-kappa B: ten years after. Cell 87(1):13-20.
4. Baeuerle PA, Henkel T. 1994. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12: 141-179.
5. Bendtzen K. 1988. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 19(3):183-191.
6. Bessler WG, Huber M, Baier W. 1997. Bacterial cell wall components as immunomodulators-II. The bacterial cell wall extract OM-85 BV as unspecific activator, immunogen and adjuvant in mice. Int J Immunopharmacol 19(9-10):551-558. (Pubitemid 28261014)
7. Bowman LM, Holt PG. 2001. Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract. Infect Immun 69(6): 3719-3727. (Pubitemid 32493290)
8. Broug-Holub E, Kraal G. 1997. In vivo study on the im-munomodulating effects of OM-85 BV on survival, inflammatory cell recruitment and bacterial clearance in Klebsiella pneumonia. Int J Immunopharmacol 19(9-10):559-564. (Pubitemid 28261015)
9. Broug-Holub E, Persoons JH, Schornagel K, Kraal G. 1995. Changes in cytokine and nitric oxide secretion by rat alveolar macrophages after oral administration of bacterial extracts. Clin Exp Immunol 101(2):302-307.
10. Denis M. 1992. Interleukin-6 in mouse hypersensitivity pneu-monitis: changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6. J Leukoc Biol 52(2):197-201.
11. Emmerich B, Pachmann K, Milatovic D, Emslander HP. 1992. Influence of OM-85 BV on different humoral and cellular immune defense mechanisms of the respiratory tract. Respiration 59 Suppl 3:19-23.
12. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, Golenbock DT. 2003. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198(7):1043-1055. (Pubitemid 37248620)
13. Gutiérrez-Tarango MD, Berber A. 2001. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest 119(6): 1742-1748. (Pubitemid 32744931)
14. Huber M, Mossmann H, Bessler WG. 2005. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur J Med Res 10(5):209-217. (Pubitemid 40753851)
15. Jara-Pérez JV, Berber A. 2000. Primary prevention of acute respiratory tract infections in children using a bacterial im-munostimulant: a double-masked, placebo-controlled clinical trial. Clin Ther 22(6):748-759 (Pubitemid 30451999)
16. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373-384.
17. Keul R, Roth M, Papakonstantinou E, Nauck M, Perruchoud AP, Block LH. 1996. Induction of interleukin 6 and inter-leukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element. Thorax 51(2):150-154. (Pubitemid 26060651)
18. Kholodenko BN. 2007. Untangling the signalling wires. Nat Cell Biol 9(3):247-249. (Pubitemid 46344602)
19. Maestroni GJ, Losa GA. 1984. Clinical and immunobiological effects of an orally administered bacterial extract. Int J Im-munopharmacol 6(2):111-117. (Pubitemid 14109021)
20. Mauël J. 1992. Macrophage activation by OM-85 BV. Respiration 59 Suppl 3:14-18.
21. Mauël J. 1994. Stimulation of immunoprotective mechanisms by OM-85 BV. A review of results from in vivo and in vitro studies. Respiration 61 Suppl 1:8-15. (Pubitemid 24296726)
22. Navarro S, Cossalter G, Chiavaroli C, Kanda A, Fleury S, Laz-zari A, Cazareth J, Sparwasser T, Dombrowicz D, Glaichen-haus N, Julia V. 2011. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol 4(1):53-65.
23. Neurath MF, Pettersson S. 1997. Predominant role of NF-kappa B p65 in the pathogenesis of chronic intestinal inflammation. Immunobiology 198(1-3):91-98. (Pubitemid 28021385)
24. Orcel B, Delclaux B, Baud M, Derenne JP. 1994. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 7(3):446-452. (Pubitemid 24099003)
25. Puigdollers JM, Serna GR, Hernandez del Rey I, Barruffet MT, Torroella JJ. 1980. Immunoglobulin production in man stimulated by an orally administered bacterial lysate. Respiration 40(3):142-149. (Pubitemid 11241285)
26. Razi CH, Harmanci K, Abaci A, Özdemir O, Hizli S, Renda R, Keskin F. 2010. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol 126(4):763-769.
27. Rozy A, Chorostowska-Wynimko J. 2008. Bacterial immunostimulants- mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol 76(5):353-359.
28. Schaad UB. 2010. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr 6(1):5-12.
29. Schaad UB, Mütterlein R, Goffin H, BV-Child Study Group. 2002. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a doubleblind, placebo-controlled multicenter study. Chest 122(6): 2042-2049. (Pubitemid 36051142)
30. Sheedy FJ, O'Neill LA. 2007. The Troll in Toll: Mal and Tram as bridges for TLR2 and TLR4 signaling. J Leukoc Biol 82(2):196-203. (Pubitemid 47230627)
31. Solèr M, Mütterlein R, Cozma G; Swiss-German OM-85 Study Group. 2007. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 74(1):26-32. (Pubitemid 46012445)
32. Tsan MF, White JE, Del Vecchio PJ, Shaffer JB. 1992. IL-6 enhances TNF-alpha-and IL-1-induced increase of Mn superoxide dismutase mRNA and O2 tolerance. Am J Physiol 263(1 Pt 1):L22-L26.
33. Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J. 1991. Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol 138(5):1097-1101.
34. Wang L, Trebicka E, Fu Y, Waggoner L, Akira S, Fitzgerald KA, Kagan JC, Cherayil BJ. 2011. Regulation of lipopoly-saccharide-induced translation of tumor necrosis factor-alpha by the toll-like receptor 4 adaptor protein TRAM. J Innate Immun 3(5):437-446.
35. Won JH, Im HT, Kim YH, Yun KJ, Park HJ, Choi JW, Lee KT. 2006. Anti-inflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Br J Pharmacol 148(2):216-225.
36. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, Akira S. 2003. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 4(11):1144-1150. (Pubitemid 37428043)
37. Zhang M, Luan H, Zhang Q, Wang L, Lv YM, He F, Chen Y, Zeng HB, Yao Y, Liu Q. 2012. Prevention of infection in immunosuppressive patients with autoimmune nephrosis by using an immunostimulating bacterial lysate: Broncho-vaxom. Hum Vaccin Immunother 8(12):1802-1807.